News

Researchers from NYU Langone published a study reporting on the eye's functioning, without sight but offering hope for the future.

According to the organization, the map and report provide public, professionals and decisionmakers with data on children’s vision issues at the county and state level.

According to research conducted by investigators at the Perelman School of Medicine at the University of Pennsylvania School of Medicine, patients with a rare inherited disease affecting their sight experienced quick vision improvements that sustained for the full year-long study.

Lynn Hassman, MD, PhD, has received the Philip and Elaine Ellis New Investigator in Ophthalmology Research Award, and will focus on seeking treatment options for uveitis patients.

Businesses in the retina care space tease new technologies and cutting-edge therapeutics

Focus on collaboration, career development, and innovation

Sujay Jadhav, CEO of Verana Health, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), provides an overview of new FDA guidance.

Research by investigators at Trinity College in Dublin shows how the gene therapy conferred significant benefit in animal models, and in human cells derived from people with glaucoma.

As part of the Barcelona meeting, retina specialists can recognise the awareness day early

The contract research organization and technology solution is for the execution of ophthalmology clinical trials.

APP13007, according to the company, is the first product developed using Formosa’s proprietary APNT nanoparticle formulation platform.

BI 771716, with technology licensed from CDR-Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.

MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.

Prevent Blindness is planning a series of events and program partnerships leading up to World Sight Day on Oct. 10, 2024.

The one-time intravitreally delivered gene therapy is for the treatment of retinitis pigmentosa (RP).

This certification covers AI based regulatory requirements for the company's platform for AI imaging and diagnostic tools.

Data from this trial will be reported ahead of AAO 2024 in Chicago, Illinois.

The 4-year study is set to involve up to 20 patients and is a part of the Foundation's Uni-Rare natural history study.

InMed Pharmaceuticals has been issued 3 US patents, one of which is for an ocular drug delivery formulation for potential use in AMD.

The day will be held on October 10. It is coordinated by the International Agency for the Prevention of Blindness under the “Love Your Eyes” campaign banner, and is putting children at the center of the campaign.

Australian researchers have found that clinical registries may be an untapped font of information for artificial intelligence.

Researchers at the Medical College of Georgia at Augusta University are teaming up with Polaris Dawn to gain a better understanding of how eye changes many astronauts experience during spaceflight could ultimately leave them with multiple symptoms once they return to Earth.

The product candidate is a modifier gene therapy for broad retinitis pigmentosa indication.

The Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial, with 18 subjects, who each have received a single periocular injection of AIV007

In this study, the investigators retrospectively analyzed the incidence of metastasis in 8,034 patients with uveal melanoma over a 35-year period based on tumor size category.

Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care.

These 4 women will feature in talks across the WIO Summer Symposium. Together they welcome all attendees to the 2024 meeting in Carlsbad, California.

The next step for the research likely will focus on determining whether blocking GSK3 can reverse existing AMD damage, potentially leading to new treatment options.

Nicole Bajic, MD, shared a bit about the skills labs at the Women in Ophthalmology Summer Symposium, the value that this meeting provides, and what she is looking forward to at this event.